ArticleJAMA network open2025
Severe Maternal Morbidity Among Pregnant People With Opioid Use Disorder Enrolled in Medicaid.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Effects of prenatal methadone and buprenorphine exposure on motivated responding for sucrose and gene expression in adult male and female rats.Addiction neuroscience · 2026Article
- Trajectories of Medication Utilization for Opioid Use Disorder in Pregnancy and Associated Maternal Outcomes.O&G open · 2026Article
- Navigating pregnancy and addiction recovery: Patient perspectives on perinatal care interventions for women with opioid use disorder in Kentucky, USA.Addiction (Abingdon, England) · 2026Article
- Adverse maternal and neonatal effects associated with perinatal xylazine exposure: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Treatment of opioid use disorder in pregnancy among individuals with and without co-occurring stimulant use disorder: A retrospective cohort study.Journal of substance use and addiction treatment · 2026Article
- Adverse Newborn Outcomes by Insurance Status Among Patients with Severe Maternal Morbidity in Maryland: 2020-2023.Healthcare (Basel, Switzerland) · 2026Article
- Maternal Opioid-related Diagnosis in Pregnancy and Risk of Adverse Perinatal Outcomes.Journal of addiction medicine · 2025Article
- Compliance and Satisfaction With a Protocol for Identifying Novel Targets to Support Postpartum Opioid Use Disorder Recovery: Prospective Cohort Study.JMIR formative research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Importance: Pregnant people with opioid use disorder (OUD) are at high risk for potentially avoidable maternal morbidity. The majority of pregnant people with OUD receive health insurance through state Medicaid programs, but there is little comprehensive data on the burden of severe maternal morbidity (SMM)-a composite measure of adverse maternal health outcomes-among this high-risk group. Objective: To estimate rates of SMM among Medicaid-enrolled pregnant people with OUD from 2016 to 2018. Design, Setting, and Participants: Using the Transformed Medicaid Statistical Information System Analytic Files, this cross-sectional study identified 96 309 pregnant people with OUD enrolled in Medicaid in 47 states with 108 975 deliveries between March 1, 2016, and November 16, 2018. Data were analyzed from August 1, 2023, to September 1, 2024. Main Outcome and Measures: SMM was identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis and procedure codes for 20 relevant conditions and was measured per 10 000 live births nationally and by state. Rates of SMM were also stratified by the timing of Medicaid enrollment before delivery. Results: From 2016 to 2018, 96 309 Medicaid enrollees had a diagnosis of OUD before a live birth (108 975 deliveries). The mean (SD) age of Medicaid-enrolled pregnant people with OUD was 28.8 (5.0) years. The mean (SD) rate of OUD among pregnant people enrolled in Medicaid was 324.8 (260.9) per 10 000 live births across states. Among this group, the mean (SD) unadjusted rate of SMM excluding blood transfusions among those with OUD was 292.1 (112.3) per 10 000 live births, with these rates varying substantially across states, from 101.0 per 10 000 live births in South Dakota to 682.2 per 10 000 live births in California. Adjustment for enrollee characteristics and comorbidities did not meaningfully alter the estimated rate of SMM (305.6 [95% CI, 245.2-408.2] per 10 000 live births). Rates of SMM generally increased with decreased durations of Medicaid enrollment. Conclusions and Relevance: This cross-sectional study of pregnant people enrolled in Medicaid found that the rate of OUD among this group was more than twice as high as previous estimates. Pregnant people with OUD face a disproportionately high risk of SMM, particularly those who enroll in Medicaid later in pregnancy. Targeted interventions that facilitate early Medicaid enrollment and coverage continuity may be needed to reduce the burden of adverse outcomes in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.